1. Home
  2. SLDP vs VIR Comparison

SLDP vs VIR Comparison

Compare SLDP & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$5.66

Market Cap

876.8M

Sector

Energy

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$6.35

Market Cap

825.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
VIR
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
876.8M
825.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SLDP
VIR
Price
$5.66
$6.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$7.00
$28.63
AVG Volume (30 Days)
5.8M
1.9M
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,802,000.00
$16,860,000.00
Revenue This Year
$4.33
N/A
Revenue Next Year
$10.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.85
N/A
52 Week Low
$0.68
$4.16
52 Week High
$8.86
$11.39

Technical Indicators

Market Signals
Indicator
SLDP
VIR
Relative Strength Index (RSI) N/A 54.17
Support Level N/A $5.69
Resistance Level N/A $6.90
Average True Range (ATR) 0.00 0.36
MACD 0.00 0.06
Stochastic Oscillator 0.00 59.16

Price Performance

Historical Comparison
SLDP
VIR

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: